Last month, medical device company Ivenix received clearance for a new smart infusion pump meant to address the safety issues endemic to the industry with more streamlined and intuitive technology.
Remember in July when the FDA issued an advisory warning of security flaws in Hospira's Symbiq smart infusion pumps? It apparently was a long time in the making, as "Hacking Healthcare," the cover story in the Nov. 16 issue of Bloomberg Businessweek, chronicles.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
This week, MedCity News covered a range of subjects, including hacking infusion pumps, pregnancy screening for genetic diseases, wearables to manage neurological disorders and the Feds trying to access Lance Armstrong's medical records.
We figured it would not be long until Hospira defended the security of its LifeCare PCA infusion pump.
The Food and Drug Administration on Friday issued an alert warning that Hospira's Symbiq Infusion System smart pumps could be vulnerable to hackers,a and recommended that healthcare facilities phase out use of the devices.
Shire adds to eye treatment portfolio with biotherapeutic deal and FDA issues safety alert for a Hospira infusion pump over concerns that it is vulnerable to a cyberattack.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The advancement of biosimilars moves another step forward today with the launch of versions of a rheumatoid arthritis and Crohn’s disease drug to European markets. The products, which come from South Korean firm Celltrion and its partners Hospira and Mundipharma, will be in competition with the Johnson & Johnson and Merck & Co. drug Remicade. […]
Leading newspapers, including the Wall St. Journal and New York Times, misunderstand the strategy behind Pfizer’s proposed purchase of Hospira. Here’s what the Journal had to say: Pfizer Inc. said Thursday it would buy smaller rival Hospira Inc. in a $16 billion deal that would transform the New York pharmaceutical company into a leading player […]
In a move to grow its biosimilar business, Pfizer just bought hospital drug supplier Hospira for $17 billion. In a way, it’s Pfizer’s do-over in miniature of its failed, $100 billion attempt last year to merge with AstraZeneca – so many of the same conversation points from that era. A Wall Street Journal article from last April wrote […]
An unlikely candidate is at the center of a capital punishment debate: propofol, the anesthesia many physicians use to put patients under. Why? A shortage on the anesthetic drugs used for lethal injection caused state governments to look elsewhere for sedatives, the Scientific American reports. Propofol, used up to 50 million times a year in US […]
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Propofol might best be known as the anesthetic Michael Jackson used inappropriately as a sleeping aid. Administered properly, the drug widely is used in hospitals to sedate patients. It also happens to be part of an industrywide drug shortage affecting hospitals throughout the country. Injectable drugs maker Hospira (NYSE:HSP) is among the dwindling number of […]
The impact of drug shortages that have left doctors and patients scrambling for life-saving drugs became much more personal and real today at a U. S. Food and Drug Administration news conference. Nebraska mother Sara Stuckey spoke at the event on behalf of her 6 -year-old son Nate, who needs a leukemia drug to survive. […]
Hospira‘s (NYSE:HSP) beleaguered Rocky Mount, North Carolina manufacturing facility has been a drag on the company’s production and its 2011 financial results, and by the looks of the company’s 2012 guidance, the site will operate below capacity for the foreseeable future as Hospira works to regain regulatory compliance. Given the extent of the problems at […]
Hospira (NYSE:HSP) completed a two-year “restructuring and optimization plan” this year that the company expressly stated would increase shareholder value by generating annualized savings between $110 million and $140 million. But now the company faces a phalanx of angry shareholders claiming the company did not disclose the extent of problems at a North Carolina plant […]
Hospira (NYSE:HSP) plans to spend up to $375 million over the next three years to bring its manufacturing facilities into regulatory compliance, the bulk of it going to a North Carolina plant saddled under heavy regulatory scrutiny for much of the last two years. The effort is under way with a hiring blitz over the […]